WilburH.ChenMD, MS, FACP, FIDSA

Infectious Disease • Baltimore, MD

International Health, Travel & Tropical

Professor of Medicine, University of Maryland School of Medicine

Join to view full profile

Dr. Chen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chen's full profile

Already have an account?

Office
Center for Vaccine Development
685 W. Baltimore Street, suite 480
Baltimore, MD 21201
Phone+1 410-706-5328

Fax+1 410-706-6205

Summary

Dr. Wilbur Chen is the Frank M. Calia, MD Endowed Professor of Medicine, an infectious disease physician-scientist at the University of Maryland School of Medicine, affiliated with the University of Maryland Medical Center. He received his medical degree from Howard University College of Medicine and has been in practice 18 years. He specializes in international health, travel & tropical and is the Director of the University of Maryland, Baltimore Travel Medicine Practice. He conducts vaccine research on diarrheal diseases, influenza, and tropical medicine.

Education & Training

University of Maryland School of MedicineMS, Clinical Research, 2004 - 2008
University of Maryland School of MedicinePost-Doctoral Fellowship, 2004 - 2006
University of MarylandFellowship, Infectious Disease, 2002 - 2004
Johns Hopkins UniversityResidency, Internal Medicine, 1999 - 2002
Howard University College of MedicineClass of 1999

Certifications & Licensure

MD State Medical License 2004 - 2026

Clinical Trials

H5N1 (Clade 2) Vaccination of Adults and Elderly Start of enrollment: 2008 Nov 01
Completed
Phase 1, Phase 2
Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59 Start of enrollment: 2010 Jun 01
Completed
Phase 1
Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations Start of enrollment: 2009 Aug 01
Completed
Phase 2
Sanofi H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations Start of enrollment: 2009 Sep 01
Completed
Phase 2
Phase I STEBVax in Healthy Adults Start of enrollment: 2011 Feb 01
Completed
Phase 1
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza Start of enrollment: 2010 Dec 01
Completed
Phase 2
Phase II Tularemia Vaccine Comparison Start of enrollment: 2010 Sep 01
Completed
Phase 2
H5N1 Mix and Match With AS03 Start of enrollment: 2011 May 01
Completed
Phase 1
Maternal Flu Vaccine Trial in Bamako, Mali Start of enrollment: 2011 Sep 12
Completed
Phase 4
Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200 Start of enrollment: 2012 Apr 01
Completed
Phase 1
Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera Start of enrollment: 2013 Sep 01
Completed
Phase 3
PXVX0200 (CVD103-HgR) vs Shanchol in Mali Start of enrollment: 2014 Jul 01
Completed
Phase 2
Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy Adults Start of enrollment: 2016 Aug 01
Completed
Phase 1
Safety, Immunogenicity and Efficacy Study of Inactivated Whole Cell Shigella Flexneri 2a Vaccine With and Without dmLT in Adults Start of enrollment: 2017 Aug 01
Withdrawn
Phase 2
A Double-Blind Placebo-Control Dose Escalating Study to Evaluate the Safety and Immunogenicity of dmLT by Oral, Sublingual and Intradermal Vaccination in Adults Residing in an Endemic Area Start of enrollment: 2019 Mar 10
Terminated
Phase 1
Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine Start of enrollment: 2022 Mar 24
Active, not recruiting
Phase 3
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

195 citations
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials
Martin R. Gaudinski, Katherine V. Houser, Kaitlyn M. Morabito, Zonghui Hu, Galina Yamshchikov
Lancet. 2017-12-05
178 citations
Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, ra...
Milagritos D. Tapia, Samba O. Sow, Boubou Tamboura, Ibrahima Téguété, Marcela F. Pasetti
The Lancet. Infectious Diseases. 2016-09-01
12 citations
Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant
Wilbur H. Chen, Lisa A. Jackson, Kathryn M. Edwards, Wendy A. Keitel, Heather Hill
Clinical and Vaccine Immunology. 2016-01-01

Journal Articles

Responses of the Human Gut Escherichia Coli Population to Pathogen and Antibiotic Disturbances
Wilbur Chen, MD, mBio

Press Mentions

Incredible Medical Advances of 2022December 23rd, 2022
Vaccines for RSV, the Illness That's Been Sickening Babies Across the US, Are Poised to Become Available in 2023November 11th, 2022
Strong RSV Vaccine Data Lifts Hopes After Years of FutilityNovember 2nd, 2022
Join now to see all